The Medicines Co.'s brisk enrollment of the confirmatory, phase III, 1,500-patient Orion-11 trial with the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor inclisiran not only bodes well for the firm but may say something about the already approved therapies in the class as well.